Astragalus

Astragalus

Astragalus

Common Names

  • Huang chi
  • huang qi
  • milk vetch
  • <em>Radix astragali</em>

For Patients & Caregivers

Bottom Line: Astragalus has immunostimulant effects, but it has not been shown to treat or prevent cancer.

Scientists believe that astragalus works by stimulating several factors of the immune system. In laboratory studies, astragalus extracts increase the activity of monocytes, natural killer cells, and lymphocytes, even when their activity is suppressed by substances such as steroids. In addition, astragalus reversed immune suppression from cyclophosphamide (a commonly used chemotherapy drug) in rats.
Astragalus extracts also protect liver cells from chemical injury in animals and in laboratory studies. Studies conducted in China suggest that astragalus may protect the kidneys when used in combination with the herb angelica. In studies using senile rats, astragalus increased the ability of their brain cells to respond to stimuli, but it is still unknown if these effects occur in humans. An herbal formula containing astragalus has been shown to reduce fatigue in athletes by increasing uptake and use of oxygen.

  • To stimulate the immune system
    Laboratory studies and some clinical trials suggest that astragalus stimulates certain parts of the immune system.
  • To reduce the severity of chemotherapy side effects, including immune suppression
    Studies in animals show that astragalus reverses the immune suppression caused by cyclophosphamide and stimulates certain parts of the immune system. Astragalus may reduce the side effects of chemotherapy in colorectal cancer patients. However, more studies are needed to confirm this effect.
  • To fight bacterial infections
    There is no evidence to support this claim.
  • To prevent and treat heart disease
    No scientific evidence supports this use.
  • To treat HIV and AIDS
    Scientific evidence to support this use is lacking.
  • To treat the common cold
    Although laboratory studies and one clinical trial suggest that astragalus stimulates certain parts of the immune system, there is no proof from clinical trials that astragalus can treat the common cold.
  • To treat diabetes
    This claim is not backed by scientific data.

Cancer treatment
This analysis was done to find out if oral Traditional Chinese Medicine formulas are effective in treating hepatocellular cancers. Forty-five randomized clinical trials involving 3,236 patients were included in the analysis. Researchers found that products containing ginseng, astragalus, mylabris and astragalus-based treatments had positive effects in patients with hepatocellular cancers.

One hundred thirty-six patients with non-small-cell lung cancer were randomized in this trial to receive vinorelbine and cisplatin (VC) or VC combined with astragalus polysaccharide injection (VC-APS). There was significant improvement in quality of life of the patients in the VC-APS group following three cycles of treatment. But no improvement was seen in tumor response or survival.

This analysis included 34 randomized studies involving 2,815 patients. Results suggest that when used along with with platinum-based chemotherapy, astragalus-based medicine improved survival, tumor response, performance status, and reduced chemotherapy toxicity when compared with chemotherapy alone.

Four clinical trials were included in a review to find out the effects of astragalus (Huangqi) compounds on the quality of life, side effects of chemotherapy, and on adverse effects in colorectal cancer patients. A decoction of Huangqi compounds was used in combination with chemotherapy in three studies, whereas the fourth study compared Huangqi compounds with two other Chinese herbal formulas. Patients who were given Huangqi compounds had less nausea and vomiting and decrease in the rate of leucopenia (low white blood cell count) compared to those treated with chemotherapy alone in the three studies or with other Chinese formulas in the fourth study.

  • You are taking immunosuppressants such as tacrolimus and cyclosporine (astragalus may lessen their effects).
  • You are taking Cyclophosphamide: Astragalus may decrease cyclophosphamide-induced immunosuppression.
  • You are taking Aldesleukin: When taken with astragalus there was a ten-fold increase in tumoricidal activity of aldeskeukin, with decreased side effects.

None known.

Back to top

For Healthcare Professionals

Astragalus membranaceus

Astragalus root has a long history of use in Traditional Chinese Medicine to increase metabolism, stamina, strength and vitality.
Studies done in China suggest that astragalus, when used with angelica, has reno protective effects (6). It also decreases the proteinuria associated with idiopathic membranous nephropathy (7) and exhibits natriuretic property (8). When used as injection, Astragalus benefits patients with IgA nephropathy (26). In other studies Astragalus was shown to suppress airway hyper reactivity associated with allergic asthma in vivo (9) and increase M-cholinergic receptor density in senile rats (11), which suggests that it may have a role in combating senility.
Astragalus extract acts as a nerve-growth promoting factor in vitro and in vivo (17), and alleviates obstructive uropathy in mice in combination with Angelica sinensis and standard care (18).
A formula containing astragalus as a major ingredient has been shown to reduce fatigue in athletes (10).

Astragalus has been studied for its anticancer potential but evidence is limited.
Astragalus extracts were shown to inhibit tumor growth (5), delay chemical-induced hepatocarcinogenesis in rats (4), and demonstrate antiangiogenic property (19). In vitro, animal, and anecdotal human data show that it reduces immune suppression, a side effect of chemotherapy (1)(2), and may also enhance the effects of platinum-based chemotherapy (3). However, Astragalus also has antioxidant activity (25). This may interfere with the actions of certain chemotherapy drugs.
Conclusions from a meta-analysis suggest benefits of astragalus-based treatments for hepatocellular cancers, but data need to be evaluated in larger, well designed trials (16).
Use of an injectable form of astragalus with vinorelbine and cisplatin in patients with advanced non-small cell lung cancer (NSCLC) (20) resulted in improvement in quality of life. However, it is not known whether orally administered astragalus will exert the same effects.
In another study, an astragalus extract was found effective in managing cancer-related fatigue (22).

Astragalus demonstrated estrogenic effects in vitro (23). Studies are needed to determine if it affects hormone-sensitive cancers.

  • Cardiovascular disease
  • Chemotherapy side effects
  • Common cold
  • Diabetes
  • HIV and AIDS
  • Immunostimulation
  • Microbial infection
  • Strength and stamina
  • Triperpenoid saponins (cycloastragenol, astragaloside I to VIII, and cyclocanthoside)
  • Cycloartane triterpene
  • Polysaccharide
  • Isoflavonoids
  • Amino acids
    (24)

Astragalus works by stimulating several factors of the immune system. The polysaccharides potentiate the immune-mediated antitumor activity of interleukin-2 in vitro (13), improve the responses of lymphocytes from normal subjects and cancer patients, enhance the natural killer (NK) cell activity of normal subjects, and potentiate the activity of monocytes (14), increasing phagocytosis perhaps by regulating tumor necrosis factor (TNF) production (5).
The saponins potentiate NK cell activity and restore steroid-inhibited NK cell activity in vitro. They also increase phagocytosis and demonstrate hepatoprotective effects on chemically-induced liver injury in vitro (6) and in vivo (4).
Studies conducted in China suggest that astragalus, when used with angelica, exerts reno protective effects by mediating gene expression. Astragaloside IV, a saponin, increases tissue-type plasminogen activator (t-PA) synthesis and downregulates the expression of plasminogen activator inhibitor type 1 (PAI-1) (21). In IgA nephropathy patients, Astragalus injection decreases Cosmc gene expression and increases IgA1 O-glycosylation level (26).
Astragalus also increases M-cholinergic receptor density in senile rats, suggesting that astragalus may have a role in combating brain senility (11).
In another study, a formula containing astragalus reduced fatigue in athletes by increasing the uptake and utility of oxygen (10).
When combined with Paeonia lactiflora, Astragalus membranaceus has synergistic antioxidant activity (25).

Adverse effects have not been reported.

  • Immunosuppressants: Theoretically, astragalus may antagonize the effects of immunosuppressants such as tacrolimus and cyclosporine.
  • Aldesleukin: Concomitant treatment with astragalus resulted in a 10-fold potentiation of tumoricidal activity with decreased side effects (14).
  • Cyclophosphamide: Astragalus may reduce cyclophosphamide-induced immunosuppression (1).

Many of the clinical trials on astragalus were conducted in China using multiple-herbal formulas that contain astragalus as the major component. The selection of herbs is based on Traditional Chinese Medicine.

Guo L, Bai SP, Zhao L, Wang XH. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival.Med Oncol. 2012 Sep;29(3):1656-62.
This study included 136 patients with confirmed non-small-cell lung cancer (NSCLS). Patients were randomized to receive vinorelbine and cisplatin (VC) or VC combined with astragalus polysaccharide APS (VC-APS). Following 3 cycles of treatment, significant differences were observed in overall quality of life (P = 0.003), physical function (P = 0.01), fatigue (P < 0.001), nausea and vomiting (P < 0.001), pain (P = 0.007), and loss of appetite (P = 0.023) between the two groups. Median survival time was 10.7 and 10.2 months (P = 0.76) in VC-APS arm and VC arm, with 1-year survival rates of 35.3 and 32.4% (P = 0.717), respectively.
Astragalus polysaccharide injection combined with vinorelbine and cisplatin may help improve quality of life in patients with NSCLC. However, there was no significant improvement in tumor response or survival rates.

Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese Medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res. 2009 Aug 12;28:112.
This analysis included 45 randomized controlled trials of oral TCM preparations for hepatocellular cancers and involved 3,236 patients. Survival, tumor response, and performance scores were examined. The authors report that products containing ginseng, astragalus and mylabris had a larger treatment effect (OR 1.34, 95% CI, 1.04-1.71, P = 0.01) than the pooled broad estimate. They observed a similar pattern for astragalus-based treatments (OR 1.35, 95% CI, 1.001-1.80. P = 0.048).
Astragalus and other TCM products may be effective against hepatocellular cancers. However, the methodology of trials was poor; all the studies were conducted in China and publication bias in favor of only positive reports is likely. The results should be evaluated in well designed trials.

McCulloch M, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: Meta-analysis of randomized trials. J clin Oncol 2006;24(3):419-430.
This analysis sought to determine whether Chinese herbal medicine containing Astragalus increases the effectiveness of platinum-based chemotherapy for advanced non-small-cell-lung cancer. Thirty-four randomized studies involving 2,815 patients were analyzed. Results suggest that when used in conjunction with platinum-based chemotherapy, Astragalus-based medicine improved survival, tumor response, performance status, and reduced chemotherapy toxicity when compared with chemotherapy alone.
However, the low quality of the studies analyzed is a drawback and the results are therefore, not conclusive. Well-designed studies are warranted.

Taixiang W, et al. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients (Review). The Cochrane Database Syst Rev 2005; (1):CD004540.
Four clinical trials were included in this review to assess the effectiveness of Astragalus (Huangqi) compounds on the quality of life, side effects of chemotherapy, and on adverse effects in colorectal cancer patients. A decoction of Huangqi compounds was used in combination with chemotherapy in three studies, whereas the fourth study compared Huangqi compounds with two other Chinese herbal formulas. Patients who were given Huangqi compounds experienced a reduction in nausea and vomiting along with a decrease in the rate of leucopenia and an increase in CD3, CD4 and CD8 subsets of T-lymphocytes when compared to those treated with chemotherapy alone in the three studies or with other Chinese formulas in the fourth study.
Use of Chinese herbal medicine along with chemotherapy appears promising for patients with colorectal cancer; however, a major limitation of this review is that it includes only four studies and the studies are of poor quality. Further properly designed trials are needed to confirm these observations.

  1. Taixiang W, Munro AJ, Guanjian L. Chinese medical herbs for chemotherapy side effects in colorectal cancer patients. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD004540.

  2. Cui R, He J, Wang B, et al. Suppressive effect of Astragalus membranaceus Bunge on chemical hepatocarcinogenesis in rats. Cancer Chemother Pharmacol. 2003 Jan;51(1):75-80.

  3. Cho WC, Leung KN. In vitro and in vivo anti-tumor effects of Astragalus membranaceus.Cancer Lett. Jul 8 2007;252(1):43-54.

  4. Ahmed MS, Hou SH, Battaglia MC, et al. Treatment of idiopathic membranous nephropathy with the herb Astragalus membranaceus. Am J Kidney Dis. Dec 2007;50(6):1028-1032.

  5. Shen HH, Wang K, Li W, et al. Astragalus Membranaceus prevents airway hyperreactivity in mice related to Th2 response inhibition.J Ethnopharmacol. Mar 5 2008;116(2):363-369.

  6. Chen KT, Su CH, Hsin LH, et al. Reducing fatigue of athletes following oral administration of huangqi jianzhong tang. Acta Pharmacol Sin. 2002 Aug;23(8):757-61.

  7. Tang W, et al. Chinese Drugs of Plant Origin. Berlin: Springer-Verlag; 1992.

  8. Qun L, Luo Q, Zhang ZY, et al. Effects of astragalus on IL-2/IL-2R system in patients with maintained hemodialysis. Clin Nephrol. 1999 Nov;52(5):333-4.

  9. Upton R. Astragalus root: analytical, quality control and therapeutic monograph. American Herbal Pharmacopoeia. 1999;1:1-25.

  10. Wu P, Dugoua JJ, Eyawo O, Mills EJ. Traditional Chinese medicines in the treatment of hepatocellular cancers: a systematic review and meta-analysis. J Exp Clin Cancer Res. 2009 Aug 12;28(1):112.

  11. Wojcikowski K, Wohlmuth H, Johnson DW, Gobe G. Effect of Astragalus membranaceus and Angelica sinensis combined with Enalapril in rats with obstructive uropathy. Phytother Res. 2010 Jun;24(6):875-84.

  12. Auyeung KK, Woo PK, Law PC, Ko JK. Astragalus saponins modulate cell invasiveness and angiogenesis in human gastric adenocarcinoma cells. J Ethnopharmacol. 2011 Aug 12.

  13. Zhang CZ, Wang SX, Zhang Y, Chen JP, Liang XM. In vitro estrogenic activities of Chinese medicinal plants traditionally used for the management of menopausal symptoms. J Ethnopharmacol. 2005 Apr 26;98(3):295-300.

  14. Xu X, Li F, Zhang X, et al. In vitro synergistic antioxidant activity and identification of antioxidant components from Astragalus membranaceus and Paeonia lactiflora. PLoS One. 2014 May 9;9(5):e96780. doi: 10.1371/journal.pone.0096780. eCollection 2014.

  15. Ji L, Chen X, Zhong X, et al. Astragalus membranaceus up-regulate Cosmc expression and reverse IgA dys-glycosylation in IgA nephropathy. BMC Complement Altern Med. 2014 Jun 18;14:195. doi: 10.1186/1472-6882-14-195.

Back to top
Back to top
Email your questions and comments to aboutherbs@mskcc.org.